BioVie Inc. has responded to the U.S. Securities and Exchange Commission (SEC) regarding comments received on their Form 10-K for the fiscal year ended June 30, 2023. The SEC's comments, dated March 13, 2024, requested that BioVie provide more detailed disclosures on their research and development expenses in future filings. Specifically, the SEC asked for costs to be disclosed for each key project or program, or if not tracked in this manner, to explain why and to provide other forms of transparency. BioVie acknowledged the SEC's feedback and confirmed its commitment to revise future filings accordingly. The company's Chief Financial Officer, Joanne Wendy Kim, communicated the response in a letter dated March 15, 2024, and offered further assistance in the review of the Form 10-K.

BioVie Inc. has responded to the U.S. Securities and Exchange Commission (SEC) regarding comments received on their Form 10-K for the fiscal year ended June 30, 2023. The SEC's comments, dated March 13, 2024, requested that BioVie provide more detailed disclosures on their research and development expenses in future filings. Specifically, the SEC asked for costs to be disclosed for each key project or program, or if not tracked in this manner, to explain why and to provide other forms of transparency. BioVie acknowledged the SEC's feedback and confirmed its commitment to revise future filings accordingly. The company's Chief Financial Officer, Joanne Wendy Kim, communicated the response in a letter dated March 15, 2024, and offered further assistance in the review of the Form 10-K.